Several psychedelic drugs are touted as effective treatments for drug and alcohol abuse. But psilocybin combined with therapy is emerging as the most effective.
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Mydecine Innovations reports its financial results for fiscal 2021 and updates investors on the company's R&D.
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
Novamind is expanding its psychedelics-based therapies into Brazil via its strategic partner in Latin America, Bienstar Wellness Corp.
Delic Expansion Accelerating into 2022 with New Clinic Openings
Delic Holdings announces two new clinics opening through its subsidiary, Ketmine Wellness Centers (KWC).
Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia
Albert Labs announces the filing of a provisional patent application for the production of Psilocybe mycelia and other fungi.
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
Enveric Biosciences announces that it has expanded on its psychedelic drug R&D pipeline along with filing a new patent application.
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
After strong preclinical testing results, Cybin is looking to advance CYB003 into a Plase 1/2a clinical trial, estimated for mid-2022.
Gold and silver head back to support
Over the past few days, gold and silver have attempted to break out to the upside but have failed. The next logical step is a return to support, $1,900 for gold and $25.5 for silver. The pattern suggests a test or a breakdown through those levels.
MindMed Reports Full Year 2021 Financial Results and Business Highlights
MindMed reports its full-year results for 2021. Progress on major R&D initiatives. Cash balance of $133.5 million.
Novamind Expands Group Therapy Model
Novamind announces plans to expand group therapy within its clinical therapy model.
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Mydecine reports conditional approval to commence a Phase IIb study on smoking cessation, in partnership with Johns Hopkins University.
